15 sep 25   genflow biosciences - genflow signs cdas with animal health companies genflow biosciences plc | genf | 0.8 0 0.0% | mkt cap: 3.86m    rns number : 2323z genflow biosciences plc 15 september 2025       15, september 2025   genflow biosciences plc    genflow signs cdas with animal health companies to advance longevity gene therapy platform   genflow biosciences plc (lse:genf) (otcqb:genff) ("genflow" or "the company"), the only publicly listed longevity company in europe, today announces that it has signed two confidential disclosure agreements (cdas) with leading animal health companies to facilitate the exchange of data and initiate discussions on potential collaborations.   these cdas mark an important milestone in genflow's strategy to leverage its proprietary sirt6-centenarian gene therapy platform for both human and animal health. building on the company's ongoing gf-1004 dog aging (beagle) study which has reported no adverse events to date. the agreements will provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving quality of life in companion animals, a rapidly growing and high-value market segment.   strategic rationale genflow's first-in-class science, when combined with the resources of a large pharmaceutical partner, offers a faster path to commercialization therefore, derisking execution and maximizing shareholder value. through such collaborations, genflow can also unlock global scale, regulatory expertise, and commercial infrastructure more quickly accelerating both revenue generation and market penetration.   dr. eric leire, ceo of genflow, commented: "the signing of these cdas reflects strong industry interest in our longevity platform and represents a further step toward building strategic partnerships in animal health. as we continue to advance gf-1004 in our canine trial, engaging with major animal health players will strengthen our pathway to potential licensing agreements and future commercialization."   contacts genflow biosciences harbor access                          dr eric leire, ceo jonathan paterson, investor relations +32-477-495-881 +1 475 477 9401  jonathan.paterson@harbor-access.com   corporate brokers  capital plus partners ltd  jon critchley, +44 207 432 0501    about genflow biosciences   founded in 2020, genflow biosciences plc. (lse:genf) (otcqb:genff), a biotechnology company headquartered in the uk with r&d facilities in belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. genflow's lead compound, gf-1002, works through the delivery of a centenarian variant of the sirt6 gene which has yielded promising preclinical results. genflow's 12-month proof-of-concept clinical trial evaluating their sirt6-centenarian gene therapy in aged dogs began in march 2025. other programs planned for 2025, include a clinical trial that will explore the potential benefits of gf-1002 in treating mash (metabolic dysfunction-associated steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. please visit www.genflowbio.com  and follow the company on linkedin and x.   disclaimer the contents of this announcement have been prepared by, and are the sole responsibility of, the company. this announcement may contain forward-looking statements. the forward-looking statements include, but are not limited to, statements regarding the company's or the directors' expectations, hopes, beliefs, intentions or strategies regarding the future. in addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. the words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. forward-looking statements include all matters that are not historical facts. forward-looking statements are based on the current expectations and assumptions regarding the company, the business, the economy and other future conditions. because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. forward-looking statements are not guarantees of future performance and the company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. in addition, even if the company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. factors or events that could cause the company's actual plans or results to differ may emerge from time to time, and it is not possible for the company to predict all of them. the company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the prospectus regulation rules, the listing rules, the disclosure guidance and transparency rules of the fca or the uk market abuse regulation.       this information is provided by reach, the non-regulatory press release distribution service of rns, part of the london stock exchange. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   nragcgdccsbdgux return to news summary

Label: Gesunken